A Study of Paravertebral Block in Thoracic Outlet Syndrome
NCT ID: NCT05544721
Last Updated: 2025-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
PHASE4
50 participants
INTERVENTIONAL
2022-10-05
2027-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Paravertebral block pre procedure
Subjects will receive a preoperative paravertebral block only
Ropivacaine
0.5% 3-4 mL per level, with levels T1 and T2 will be used as the block injectate
Paravertebral block pre and post procedure
Subjects will receive one paravertebral block, administered preoperatively and one paravertebral block, administered on postoperative day 1
Ropivacaine
0.5% 3-4 mL per level, with levels T1 and T2 will be used as the block injectate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ropivacaine
0.5% 3-4 mL per level, with levels T1 and T2 will be used as the block injectate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with prior first rib resection on side of presentation.
* Patients with complex regional pain syndrome (CRPS).
* Patients with brachial plexus disorder.
* Patients with cervical rib.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Houssam Farres, M.D.
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Houssam Farres, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Florida
Jacksonville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-006685
Identifier Type: -
Identifier Source: org_study_id